LIPO Lipella Pharmaceuticals Inc

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

Lipella Pharmaceuticals Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

53630L209

(CUSIP Number)

 

September 30, 2024

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

 

^* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

  

CUSIP No. 53630L209

13G/A

Page 2 of 6 Pages

1.	NAMES OF REPORTING PERSONS Michele Gruber
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER   46,875 (1)
	6.	SHARED VOTING POWER 0
	7.	SOLE DISPOSITIVE POWER   46,875 (1)
	8.	SHARED DISPOSITIVE POWER 0

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 46,875 (1)
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.9% (2)
12.	TYPE OF REPORTING PERSON (see instructions) IN

 

(1) Consists of 46,875 shares of the issuer’s common stock, par value $0.0001 per share (“Common Stock”), that may be issued upon the exercise of stock options awarded by the issuer to the reporting person in such person’s capacity as an employee of the issuer, which are vested and exercisable, or will be vested and exercisable, for such shares of Common Stock within 60 days of the date of event that requires the filing of this Amendment No. 2 to Statement on Schedule 13G (this “Amendment No. 2”).

 

(2) This constitutes an exit filing for the reporting person. The percentage set forth in row (11) is based on 1,208,943 shares of the issuer’s Common Stock, outstanding as of November 11, 2024, as disclosed in the issuer’s definitive proxy statement on Schedule 14A, filed by the issuer with the U.S. Securities and Exchange Commission (the “SEC”) on November 12, 2024, and reflects the issuer’s 1-for-8 reverse stock split of its outstanding shares of Common Stock that was effected on November 7, 2024. All 46,875 shares of Common Stock that the reporting person has the right to acquire within 60 days of the date of event that requires the filing of this Amendment No. 2 pursuant to the exercise of stock options held by the reporting person are deemed to be outstanding for purposes of calculating such beneficial ownership percentage.

CUSIP No. 53630L209

13G/A

Page 3 of 6 Pages

 

This Amendment No. 2 to Statement on Schedule 13G (“Amendment No. 2”) amends and supplements the Statement on Schedule 13G filed by the reporting person with the U.S. Securities and Exchange Commission (the “SEC”) on March 29, 2023 (the “Schedule 13G”), as amended and supplemented by Amendment No. 1 to the Schedule 13G, filed by the reporting person with the SEC on February 7, 2024 (“Amendment No. 1”). Except as otherwise set forth herein, this Amendment No. 2 does not modify any of the information previously reported by the reporting person in the Schedule 13G or Amendment No. 1.

 

The purpose of this Amendment No. 2 is to update the reporting person’s beneficial ownership information on the cover page and in Item 4 of the Schedule 13G and Amendment No. 1, including to reflect the issuer’s 1-for-8 reverse stock split of its outstanding shares of Common Stock that was effected on November 7, 2024, as well as to update Item 2(e) in respect of such reverse stock split. This Amendment No. 2 constitutes an exit filing for the reporting person.

 

Item 1

 

(a)

Name of Issuer:

 

Lipella Pharmaceuticals Inc. (the “Issuer”)

 

(b)

Address of Issuer’s Principal Executive Offices:

 

7800 Susquehanna Street, Suite 505

Pittsburgh, Pennsylvania 15208

 

Item 2. Names of Persons Filing:

 

(a)

Name of Person Filing:

 

Michele Gruber (the “Reporting Person”)

  

(b)

Address of Principal Business Office or, if none, Residence:

 

7800 Susquehanna Street, Suite 505

Pittsburgh, Pennsylvania 15208

 

(c)

Citizenship:

 

United States of America

 

(d)

Title of Class of Securities:

 

Common stock, par value $0.0001 per share, of the Issuer

 

(e)

CUSIP Number:

 

53630L209

  

CUSIP No. 53630L209

13G/A

Page 4 of 6 Pages

 

Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

Not applicable.

 

Item 4. Ownership.

 

(a)

Amount beneficially owned: 46,875

(b)

Percent of class: 3.9%

(c)

Number of shares as to which the Reporting Person has:

a.

Sole power to vote or to direct the vote: 46,875

b.

Shared power to vote or to direct the vote: 0

c.

Sole power to dispose or direct the disposition of: 46,875

d.

Shared power to dispose or direct the disposition: 0

  

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

  

  

CUSIP No. 53630L209

13G/A

Page 5 of 6 Pages

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

  

  

CUSIP No. 53630L209

13G/A

Page 6 of 6 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: November 14, 2024
	/s/ Michele Gruber
	Name: Michele Gruber

  

---